BTG gets triple dose of good news on new products

14 Dec, 2015 11:28 am

LONDON – Specialist medicine company BTG (BTG.L) received a triple dose of good news on Monday as US regulators approved two new treatments and a clinical trial of a novel lung device produced positive results.

US green lights for Vistogard and Lumi, for chemotherapy overdoses and tumours, and the success of PneumRx coils in severe emphysema may go some way to counter recent disappointment over sales of BTG’s varicose vein treatment Varithena. -Reuters

Must Watch